Anton Leighton

Dr. Leighton is an infectious disease doctor who has held clinical development and leadership roles at Ciba-Geigy (now Novartis), Roche (US Head Infectious Diseases and Inflammation), and Chiron. He has since established his own consulting company and supported a number of early phase antibiotics and biologics, during which he was involved in the selection of lead candidates, development of regulatory strategy, interaction with regulatory authorities, and setup and conduct of ICU-based clinical studies regarding serious infections and sepsis.

He currently is a consultant to several biotech companies in the San Francisco Bay area. His clinical experience includes the following IV antibiotics: iclaprim, dalbavancin, doripenem and eravacycline. His experience with biologics includes a TNF receptor fusion protein and tifacogin. Dr. Leighton has a medical degree from the University of Mainz, certification in internal medicine from university-affiliated hospitals in Germany, a degree in pharmaceutical medicine from the University of Basel, Switzerland, and a Healthcare Executive MBA from the University of California, Irvine.